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Background: Epidermodysplasia verruciformis is a rare genodermatosis characterized by a unique susceptibility to
cutaneous human papillomaviruses infection. Most patients show autosomal recessive patterns of inheritance.
Case presentation: We report a case of two sisters with clinically epidermodysplasia verruciformis specific lesions
on the face, neck, trunk, and extremities. PCR analysis indicated the presence of human papillomavirus type 5 in the
lesions. Electron microscopic examination showed viral-like particles in keratinocyte nuclei and the stratum corneum of
the epidermodysplasia verruciformis lesions. In addition, we examined the EVER1 and EVER2 genes using eight different
primer pairs without finding any nonsense or frameshift mutations in the gDNA from lymphocytes of the elder sister.
Conclusions: In this report, the patient’s parents did not have epidermodysplasia verruciformis lesions or a
consanguineous marriage. EV did not develop in the elder sister until five years of age, so the parents did not perceive
EV as an inherited disease. The probability that EV developed in both sisters was only 6.25%. Thus, it is rare for both
sisters to develop epidermodysplasia verruciformis lesions considering that the parents were presumed to be carriers
and the disease reveal an autosomal recessive pattern of inheritance.
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Electron microscopic examinationBackground
Epidermodysplasia verruciformis (EV) is an uncommon
cutaneous disorder characterized by persistent infection
with beta-human papillomavirus (HPV) and a combi-
nation of flat wart-like lesions, pityriasis versicolor-like
lesions, hypopigmented macules, or other erratic skin
lesions. These lesions are mainly located on the face,
neck, and extremities [1,2]. Most patients demonstrate
autosomal recessive patterns of inheritance, although
some exhibit X-linked recessive or autosomal dominant
inheritance [3,4]. Cutaneous carcinomas in situ or inva-
sive carcinomas, which are usually of the Bowen’s
disease-type, generally appear in a high percentage of
patients, before the age of 40 [1,2,5]. More than 40 beta-
papillomaviruses have been identified in patients with
EV [6]. Among them, HPV5 and HPV8 are primarily
involved in the malignant transformation associated with
EV. HPV9 is also often involved in EV [1,2].* Correspondence: tmitsu@tymc.twmu.ac.jp
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unless otherwise stated.The EVER1 and EVER2 genes were found to be
responsible for EV in 2002 [7]. EVER1 and EVER2 are also
referred to as TMC6 and TMC8, respectively, and are
located on chromosomes 17q25 [7]. Various mutations in
the EVER1 and/or EVER2 genes reportedly contribute to
HPV-associated EV [8-10]. In this study, we report a case
of two sisters with both EV and HPV5 infections whose
parents did not have EV lesions. We observed viral-like
particles in the lesions by electron microscopic exami-
nation. We also assessed the mutational status of the
EVER1 and EVER2 genes from extracted blood cells using
PCR with eight different primers.
Case presentation
Case 1
A 29-year-old female has had asymptomatic, slightly
erythematous, and hypopigmented pityriasis versicolor-
like lesions on her face, neck, trunk, and extremities since
the age of five as well as multiple brownish-black, hype-
rkeratotic, papular plaque, wart-like lesions on the extre-
mities. The lesions progressively increased in number and
size with age (Figure 1A, B). No abnormalities werel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Clinicohistological findings in two sisters. (A) Asymptomatic, slightly erythematous, and hypopigmented pityriasis versicolor-like
lesions on the neck in the elder sister. (B) Left upper arm of the elder sister showing numerous round pigmented macules with slight scale.
(C) Histological findings show epidermal hyperplasia and distinct homogenous intracytoplasmic inclusion bodies in the large clear cells of the
epidermis (arrows); scale bar = 100 μm. (D) Multiple brown, flat wart-like lesions on the face of the younger sister.
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membranes, and other systems, including abdominal
echography and chest X-ray. Histopathology of a flat
wart-like lesion showed marked hyperkeratosis, mild
acanthosis, and the presence of distinct homogeneous
intracytoplasmic inclusion bodies in the large clear cells
of the epidermis (Figure 1C). Additional systemic exa-
minations and laboratory investigations, including an
HIV test, were all normal. Topical 5-fluorouracil (5-FU)
and imiquimod 5% cream were applied to the small
pityriatic or flat wart-like lesions for three days per week
at Jikei University School Hospital and Nippon Medical
School Hospital. The lesions gradually decreased in size
and number. She has been applying ultraviolet (UV)
blocker most days and is being followed by Nippon
Medical School Hospital.
Case 2
The 23-year-old sister of case 1 has had similar cutaneous
lesions since the age of six. Multiple asymptomatic, ery-
thematous, pityriasis versicolor-like lesions and flat wart-
like lesions were found on the face, trunk, and extremities
(Figure 1D). These lesions also increased progressively in
number and size. A biopsy of the EV lesions showed focal
cellular atypia in the flat wart-like lesions with abnormal
mitotic figures in the large clear cells of the epidermis.
Topical 5-FU and imiquimod 5% cream were prescribed
for application twice daily on the lesions. She has beenapplying UV blocker almost every day. Interestingly,
neither parents of the two patients showed EV lesions,
but both were carriers.
Genetic investigations
We performed PCR using two different primers, CP65/
70 and SK, to determine the prevalence of HPV infec-
tion [11,12]. Frozen tissues from the EV cutaneous le-
sions of both patients were digested with proteinase K
(100 mg/ml), and genomic DNA (gDNA) was extracted
with phenol-chloroform-isoamyl alcohol. The gDNA
was then precipitated with ethanol as previously de-
scribed [12]. The primer sets amplified DNA products
from alpha-, beta-, and gamma-HPVs. The PCR pro-
ducts were sequenced with an ABI model 3730xl
automated DNA sequencer (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s instruc-
tions. The result of the PCR analysis indicated that HPV5
infection was present in the flat wart-like lesions and pity-
riasis versicolor-like lesions from the lesions in both sisters.
After informed consent was obtained, gDNA from the
peripheral blood of the elder sister was acquired accor-
ding to the manufacturer’s instructions. The presence of
EVER1 and EVER2 mutations was analyzed by PCR with
six known primers [8-10] and two new primers, which
were designed against GenBank sequences (NM_152468)
for TMC8/EVER2. The new primers used for amplifica-
tion of the gDNAs were as follows: EVER2, exon 8-1 F, 5’-
Figure 2 Electron microscopy image showing typical virus-like
particles with crystalline array (arrows) filling the stratum
corneum; scale bar = 1 μm.
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TTG TTG TCC TGT GAG TAC TTG-3’; exon 8-2 F, 5’-
GTT TCC TGC ACC CTT TCC TC-3’; exon 8-2R, 5’-
TAC TTG GTA GCC CAG AAG ATG G-3’. The PCR
products from the two new primers were 170 bp and
211 bp in length, respectively. The PCR products were
run on 2% agarose gels and purified with the QIAquick
Gel Extraction Kit (Qiagen, Hilden, Germany). Sequen-
cing analysis was carefully performed in both directions
and compared with the known sequences registered in
GenBank. We did not identify any nonsense or frame-
shift mutations in any of the eight target bands.
Electron microscopic examination
Electron microscopy was performed on a lesion from
the skin of the elder sister. The specimens were fixed
with 2.5% glutaraldehyde and postfixed with 1% osmium
tetroxide. The samples were then dehydrated through a
graded alcohol series and embedded in Epon 812. Ultra-
thin sections were cut using an Ultracut N Ultramicro-
tome (Reihert-Nissei, Tokyo, Japan) and were stained
with uranyl acetate and lead citrate. The sections were
then examined by electromicroscope (Hitachi H-7500;
Hitachi, Tokyo, Japan). The results of the electron
microscopy showed typical virus-like particles with crys-
talline arrays filling the nuclei of the keratinocyte cells in
the upper epidermis and stratum corneum. Large, clear
dysplastic cells were also observed in the flat wart-like
lesions (Figure 2).
Discussion
Malignant cutaneous lesions in patients with EV are
preferentially located on sun-exposed areas. The deve-
lopment of malignant transformation in EV patients is
primarily associated with HPV5 and HPV8 infection.
PCR analysis indicated that HPV5 infection was present
in flat wart-like lesions and pityriasis versicolor-like lesions
of our patients; however, malignant cutaneous lesions
were not found in sun-exposed areas. Most patients have
autosomal recessive inheritance patterns for EV. However,
a small number of patients show X-linked recessive or
autosomal dominant inheritance [3,4]. The parents of the
patients in our study were presumed to be carriers, but
did not develop EV lesions. In addition, the parents did
not form a consanguineous marriage. Based on autosomal
recessive patterns of inheritance, we would expect 25% of
children to develop EV lesions. In this family, these sisters
are the only offspring, and the mother did not have a
history of miscarriage. EV did not develop in the elder
sister until five years of age. Thus, the parents did not
identify EV as a disease of inheritance.
The EVER1 and EVER2 genes associated with EV
belong to the transmembrane channel-like (TMC) gene
family and are called TMC6 and TMC8, respectively.The albuminous functions encoded by EVER1 and
EVER2 remain unknown. The presence of EVER gene
mutations in patients with EV suggests that beta-HPV
infection is linked to the progression of non-melanoma
skin cancer. Some reports indicate the relationship
between mutations in the EVER2 gene and the risk of
cutaneous squamous cell carcinoma [13,14]. After care-
ful examination for the presence of EVER1 and EVER2
genes by PCR followed sequence analysis in both direc-
tions, we did not observe any nonsense or frameshift
mutations in any of the target bands. Although there is
no curative therapy for EV, protection from UV light
and treatment of EV-specific cutaneous lesions is neces-
sary from an early stage. Nonsurgical approaches include
topical imiquimod, 5-FU, vitamin D3, cimetidine, systemic
retinoids, and interferon [14-18]. Some reports show
success with topical imiquimod in immunocompetent pa-
tients with squamous cell carcinoma in situ [14,19]. In this
study, imiquimod 5% cream was applied once per day and
three days per week for flat wart-like lesions. Oral reti-
noids (0.5 mg/kg) were also prescribed. Cutaneous lesions
decreased in size after a short period; however, relapse of
the cutaneous lesions of patients occurred after 1 year,
suggesting that the therapy was not effective. Importantly,
both patients applied UV blocker daily.
Conclusions
Most EV patients show autosomal recessive patterns of
inheritance; although, some patients can exhibit X-linked
recessive or autosomal dominant inheritance. In the two
cases described here, two sisters with EV had parents
without EV lesions that were are not in a consanguineous
marriage. Furthermore, the mother does not have a his-
tory of miscarriage. EV did not develop in the elder sister
until five years of age. The probability of EV developing in
both sisters was only 6.25%. Thus, it is rare for both sisters
to develop EV lesions, despite that both parents were
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somal recessive pattern of inheritance. No nonsense or
frameshift mutations in the EVER2 gene were identified
using two new primers, however, there may be some risk
of developing cutaneous squamous cell carcinoma from
benign EV lesions. Long-term follow-up will be necessary
for both sisters.
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